sirolimus国内上市了吗？

Sirolimus was approved in 2002 and officially launched in China. The current reference price of the drug in China is between 143.00$ and 2739.00$. Patients can reimburse part of the cost through medical insurance, and only pay about 20% out of pocket. Due to the influence of regional medical insurance policies and other factors, there will be certain differences in the final reimbursement ratio of this drug. Specific patients can consult the relevant departments.

As a mammalian target of rapamycin (mTORi) inhibitor, although rapamycin has a similar structure to tacrolimus, its immunosuppressive mechanism is completely different from that of tacrolimus. Tacrolimus plays a role by inhibiting calcineurin, blocking interleukin 2 (IL-2)-mediated calcium ion-dependent T lymphocyte transcription and activation-related signaling pathways. However, it will also affect normal ion channel function and cell secretion, leading to adverse reactions such as nephrotoxicity. However, sirolimus does not bind to calcineurin, but binds to the mammalian target of rapamycin (mTOR), thereby blocking the transition of T lymphocytes and other cells from the G1 phase to the S phase without causing nephrotoxicity. Some studies have shown that mTORI can significantly increase GFR levels when replacing CNI.

Another study conducted abroad showed that compared with the tacrolimus group, recipients in the sirolimus group had a higher incidence of AR. Domestic studies have similar results, and are an important reason for recipients to withdraw from the sirolimus group. This is related to the failure of recipients in the sirolimus group to reach the target blood concentration of the drug. Setting an appropriate target blood concentration and closely monitoring the blood concentration will effectively prevent the occurrence of AR in recipients in the sirolimus group and reduce the dropout rate of recipients.

Based on this, patients must use sirolimus strictly in accordance with the instructions or doctor's advice, so that its efficacy can be fully exerted.